Daval International is a UK based biotechnology company focused on the development of novel treatments for serious unmet medical needs. Daval’s lead product AIMSPRO has completed two proof of concept Phase II trials, the first for the treatment of Systemic Sclerosis and the second for Secondary Progressive Multiple Sclerosis. An investigator led open label trial […]![]()
